Biotechnology

IN8bio

IN8bio released FY2025 9 Months earnings on November 6, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -4.0804

IN8bio released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8493 (forecast USD -1.245)

IN8bio Adds Ohio State University as Clinical Trial Site

Analyst Ear Covers Healthcare Industry and Focuses on Specific Stocks

IN8bio released FY2025 Semi-Annual earnings on August 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.645

IN8bio released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.24 (forecast USD -1.8)

IN8bio announces patient status in phase 1 clinical trial for newly diagnosed glioblastoma

IN8bio's Experimental Drug Achieves 4-Year Remission for Glioblastoma Patient

IN8bio INB-200 I Phase Trial for GBM Shows Positive Progress

IN8bio released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.1 (forecast USD -2)

IN8BIO Inc. Reports Reduced Net Loss in Q1 2025

IN8BIO Inc. revises security purchase agreement

Analysts Rate IN8bio as 'Buy' with a Price Target of $3.62

IN8bio released FY2024 Q4 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.3963 (forecast USD -2.25)

IN8bio released FY2024 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.0525 (forecast USD -16.8)

IN8bio, Inc. Launches New γδ T Cell Therapy Platform INB-600

Jones Trading Upgrades IN8bio (INAB.US) Rating to Buy with Target Price of $1.20

IN8bio released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.4923 (forecast USD -4.9)

IN8bio released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -16.2288

IN8BIO Announces Clinical Pipeline Prioritization and Layoffs

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap